Arcadia Biosciences (RKDA) Misses Q4 EPS by 12c

Arcadia Biosciences (NASDAQ: RKDA) reported Q4 EPS of ($0.42), $0.12 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $2.17 million versus the consensus estimate of $3.33 million.

For earnings history and earnings-related data on Arcadia Biosciences (RKDA) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• What Delta’s report tells investors in American and United
• FDA approves Padcev plus Keytruda for muscle-invasive bladder cancer